Straumann Holding AG (SAUHF)
154.60
-4.55
(-2.86%)
USD |
OTCM |
Mar 28, 09:45
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 24.65B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 15.64% |
Valuation | |
PE Ratio | 90.02 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 9.131 |
Price to Book Value | 11.28 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.9667 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.1089 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 61.15% |
Profile
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds nearly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.2 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 12% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands. |
URL | https://www.straumann-group.com |
Investor Relations URL | https://www.straumann.com/group/en/home/investors.html |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Equity Style | Large Cap/Growth |
Next Earnings Release | Apr. 30, 2024 |
Last Earnings Release | Feb. 27, 2024 |
Next Ex-Dividend Date | Apr. 16, 2024 |
Last Ex-Dividend Date | Apr. 11, 2023 |
Ratings
Profile
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds nearly 30% of the global implant dentistry market, which is estimated to be worth roughly CHF 5.2 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 12% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands. |
URL | https://www.straumann-group.com |
Investor Relations URL | https://www.straumann.com/group/en/home/investors.html |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Equity Style | Large Cap/Growth |
Next Earnings Release | Apr. 30, 2024 |
Last Earnings Release | Feb. 27, 2024 |
Next Ex-Dividend Date | Apr. 16, 2024 |
Last Ex-Dividend Date | Apr. 11, 2023 |